10-Q: Dynavax Reports Strong HEPLISAV-B Sales, Strategic Pipeline Expansion

Dynavax Technologies Corporation reported a 53% increase in net income for Q3 2025 driven by robust HEPLISAV-B sales, despite a nine-month net loss due to a significant debt extinguishment charge and bad debt expense.

Summary

• Total revenues for the three months ended September 30, 2025, increased by 18% to $94.9 million, compared to $80.6 million for the same period in 2024.
• Product revenue from HEPLISAV-B, net, grew by 13% to $89.9 million for Q3 2025, up from $79.3 million in Q3 2024, primarily due to higher volume and increased net sales price.
• Other revenue saw a substantial increase of 283% to $4.9 million for Q3 2025, largely from the U.S. Department of Defense (DoD) agreement.
• Net income for the three months ended September 30, 2025, was $26.9 million, a 53% increase from $17.6 million in the prior year period.
• For the nine months ended September 30, 2025, total revenues increased by 26% to $258.5 million, compared to $205.2 million for the same period in 2024.
• A net loss of $50.5 million was recorded for the nine months ended September 30, 2025, primarily due to an $82.1 million loss on debt extinguishment and an $11.0 million bad debt expense related to the Clover contract asset.
• Cash and cash equivalents, and marketable securities totaled $647.8 million as of September 30, 2025, an increase from $95.9 million in cash and cash equivalents at December 31, 2024.
• The company completed a refinancing transaction for its convertible notes, issuing $225.0 million of 2.00% Convertible Senior Notes due 2030 and unwinding capped call options for $46.6 million in cash proceeds.
• An allowance for doubtful accounts of $11.0 million was recorded for the contract asset related to Clover Biopharmaceuticals due to GAVI's termination of Clover's advanced purchase agreement option and Clover's liquidity position.
• Dynavax authorized a new share repurchase program of up to $100.0 million in October 2025, following the completion of a previous $200.0 million program.
• Entered into an exclusive worldwide license agreement with Vaxart, Inc. in November 2025 to develop and commercialize oral vaccines for coronavirus and respiratory illnesses, including a $25.0 million upfront fee and a $5.0 million equity investment.

Sentiment

Score: 6

Explanation: The filing presents a mixed picture. Strong core product performance (HEPLISAV-B revenue growth, Q3 net income) and strategic pipeline advancements (shingles vaccine data, Vaxart deal, new share repurchase program) are positive. However, the significant nine-month net loss due to one-time debt extinguishment and the $11.0 million bad debt expense related to Clover are notable negatives. The overall financial position remains solid with substantial cash and marketable securities, but the one-off charges and the uncertainty around CpG 1018 adjuvant revenue temper the positive developments.

Positives

• HEPLISAV-B product revenue increased by 13% for Q3 2025 and 25% for the nine months ended September 30, 2025, driven by higher volume and net sales price, indicating strong market uptake.
• Operating income for Q3 2025 more than doubled to $21.3 million from $10.1 million in Q3 2024, demonstrating improved operational efficiency and profitability in the quarter.
• Net income for Q3 2025 increased by 53% to $26.9 million, reflecting strong quarterly performance.
• Successful refinancing of convertible notes extends maturity to 2030, reducing near-term debt obligations and providing financial flexibility.
• Positive topline data from Part 1 of the Phase 1/2 clinical trial for the shingles vaccine candidate (Z-1018), showing favorable tolerability and robust immune responses comparable to Shingrix.
• Progress in the plague vaccine program with the U.S. Department of Defense, including a $14.0 million amendment for additional clinical activities and completion of Phase 2 enrollment.
• Completion of Part 1 of the Phase 1/2 study for the pandemic influenza adjuvant program, advancing to Part 2 with data expected in 2026.
• Initiation of IND-enabling studies for the Lyme disease vaccine candidate, with clinical development planned for 2027.
• FDA feedback in Q1 2025 indicating that the proposed patient database may be acceptable for the HEPLISAV-B hemodialysis observational retrospective cohort study, potentially addressing previous regulatory deficiencies.
• Authorization of a new $100.0 million share repurchase program in October 2025, signaling confidence in financial health and commitment to shareholder returns.
• Strategic licensing agreement with Vaxart, Inc. for oral coronavirus vaccines expands the pipeline and leverages the Vaxart Platform for new indications.

Negatives

• A net loss of $50.5 million was reported for the nine months ended September 30, 2025, primarily due to a one-time $82.1 million loss on debt extinguishment and an $11.0 million bad debt expense.
• Recorded an $11.0 million allowance for doubtful accounts related to the Clover contract asset, reflecting increased credit risk due to GAVI's termination of Clover's advanced purchase agreement option and Clover's liquidity.
• No CpG 1018 adjuvant revenue was recognized in 2024 or during the nine months ended September 30, 2025, indicating a significant drop from prior periods during the COVID-19 pandemic.
• The commercialization agreement with Bavarian Nordic for HEPLISAV-B in Germany was not renewed, with rights reverting to Dynavax in April 2026, potentially impacting international revenue streams.
• Research and development expenses increased by 29% for the nine months ended September 30, 2025, to $55.1 million, reflecting higher investment in pipeline programs.
• Selling, general and administrative expenses increased by 7% for the nine months ended September 30, 2025, to $138.1 million, primarily due to $12.5 million in professional consulting and legal fees related to a proxy contest campaign.
• The 2026 Convertible Senior Notes, with a principal balance of $40.2 million, were reclassified from long-term to current liabilities as they mature within 12 months, impacting current liquidity ratios.

Risks

• HEPLISAV-B faces significant competition in the U.S., the only geographic region where it is currently marketed, and its commercial success is unpredictable.
• Financial results may vary significantly from quarter to quarter or fall below expectations due to factors like unpredictable product uptake, timing of revenue recognition, and fluctuations in expenses.
• The company has incurred annual net losses in most years since inception and may continue to incur significant losses if HEPLISAV-B commercialization, new product launches, or CpG 1018 adjuvant sales do not resume consistently.
• Many competitors have greater financial resources and expertise, potentially harming Dynavax's ability to generate sufficient revenue.
• Reliance on the Dsseldorf facility and third parties for manufacturing, including a limited number of suppliers for oligonucleotides and a single contract manufacturer for pre-filled syringes, poses supply chain risks.
• Difficulties in managing commercial growth and expanding operations successfully could hinder the commercialization of HEPLISAV-B and CpG 1018 adjuvant.
• Supply agreements with customers carry delivery obligations, and failure to deliver timely, compliant products could lead to lost revenue, penalties, and reputational harm.
• Uncertainty regarding coverage, pricing, and reimbursement from third-party payors may make it difficult to sell products on commercially reasonable terms, especially for new products or in international markets.
• Ongoing FDA, EU, and foreign post-marketing obligations for HEPLISAV-B may result in significant additional expense and potential penalties for non-compliance.
• HEPLISAV-B and all clinical programs rely on oligonucleotide TLR agonists, and serious adverse events related to these could require reducing or discontinuing operations.
• Regulatory authorities may require more clinical trials or extended trials for product candidates, leading to substantial delays and impaired revenue generation.
• Clinical trials are expensive, time-consuming, and have uncertain outcomes, with potential for delays, unexpected adverse events, or inconclusive results.
• Reliance on collaborative relationships for product development and commercialization may not succeed, limiting the ability to advance programs.
• Financial commitments for manufacturing and supply capacity might outpace actual demand for products, leading to unrecovered costs or write-offs.
• Developing, seeking regulatory approval for, and marketing products outside the U.S., EU, and UK requires significant resources and carries risks related to international operations.
• Reliance on CROs and clinical sites for clinical trials means their failure to meet obligations or deadlines could delay planned trials and regulatory approvals.
• Global trade issues, changes in trade policies, and export regulations (including potential pharmaceutical tariffs) could increase costs, reduce competitiveness, and adversely affect financial results.
• Failure to comply with healthcare fraud and abuse, anticorruption, privacy, transparency, and other laws could lead to significant liability.
• Grants received may involve pricing or other restrictions, potentially limiting control over product pricing and distribution.
• Enacted or future legislation, including unfavorable pricing regulations or healthcare reform initiatives (e.g., IRA, Loper Bright decision), may adversely affect operations and business.
• As a defense contractor for the DoD, the company is subject to additional administrative burdens and control requirements, with limited experience in managing such programs.
• Product liability exposure, if not adequately covered by insurance, could result in significant financial liability.
• Third-party assertions of patent infringement or challenges to Dynavax's patents could lead to costly disputes and litigation, impacting commercialization.
• Inadequate protection of intellectual property through patents, trade secrets, and contractual provisions could decrease product value.
• Reliance on licenses from third parties means impairment or inability to obtain/maintain these licenses could severely harm the business.
• Claims of wrongful use or disclosure of trade secrets by employees or consultants could be costly to defend and result in loss of intellectual property or personnel.
• Stock price is subject to volatility due to numerous factors, including clinical trial results, regulatory approvals, competition, and macroeconomic conditions.
• Future sales of common stock or the perception of such sales could depress the stock price.
• Servicing Convertible Notes requires significant cash flow, and the company may not have sufficient funds to meet these obligations or repurchase notes upon a fundamental change.
• Conditional conversion features of Convertible Notes may adversely affect financial condition and operating results, potentially requiring cash payments or reclassification to current liabilities.
• Conversion of Convertible Notes may dilute ownership interest of stockholders or depress the stock price.
• Provisions in indentures governing Convertible Notes may delay or prevent beneficial takeover attempts.
• Capped call options may affect the value of Convertible Notes and common stock, and the company is subject to counterparty risk.
• Loss of key personnel could delay or prevent achieving objectives, and continued growth may lead to difficulties in managing operations.
• Business operations are vulnerable to interruptions by natural disasters, health epidemics, and other catastrophic events, which could harm manufacturing, distribution, sales, and financial results.
• Compromised information technology systems or data could lead to regulatory investigations, litigation, fines, disruptions, and reputational harm.
• Adverse developments affecting the financial services industry may have adverse consequences on the business, financial condition, and stock price.

Future Outlook

Dynavax anticipates that its cash, cash equivalents, marketable securities, and projected HEPLISAV-B revenues will fund operations for at least the next 12 months. The company expects HEPLISAV-B to achieve at least 60% total market share in the U.S. by 2030, with the market opportunity remaining substantial beyond that due to ongoing penetration of the unvaccinated adult population and continued market share gains. Research and development expenses are expected to increase as the clinical and preclinical pipeline advances, including anticipated topline Part 2 results and 12-month follow-up data for the shingles vaccine in H2 2026, and clinical development for the Lyme disease vaccine in 2027. The company also expects topline immunogenicity and safety data for Part 2 of the pandemic influenza program in 2026. Future demand for CpG 1018 adjuvant is uncertain and highly dependent on collaborators' ability to commercialize vaccines.

Management Comments

• "Our annual revenue has continued to grow significantly since the recommendation was made, primarily as a result of our successful efforts to capture a greater share of an expanding market."
• "We believe this is helping create a significantly expanded total annual market opportunity of approximately $900.0 million in the U.S. by 2030, with HEPLISAV-B expected to achieve at least 60% total market share."
• "We expect research and development costs to increase further if we add additional programs to our pipeline."
• "We intend to continue to pursue collection of the full $71.3 million due from Clover."
• "We currently anticipate that our cash and cash equivalents, and short-term marketable securities as of September 30, 2025, and anticipated revenues from HEPLISAV-B will be sufficient to fund our operations for at least the next 12 months from the date of this filing."

Industry Context

The biopharmaceutical industry continues to see strong demand for innovative vaccines, particularly in areas like hepatitis B, shingles, and emerging infectious diseases. Dynavax's HEPLISAV-B is benefiting from the CDC's universal recommendation for hepatitis B vaccination in adults, expanding its market opportunity. The company's focus on its CpG 1018 adjuvant positions it to capitalize on the ongoing need for enhanced vaccine efficacy, as evidenced by its collaborations with the DoD and the recent Vaxart agreement for oral coronavirus vaccines. However, the market for COVID-19 vaccine adjuvants has seen a significant decline in demand, impacting Dynavax's CpG 1018 adjuvant revenue. The industry also faces increasing scrutiny over pharmaceutical pricing, data privacy, and geopolitical trade policies, which could affect global supply chains and market access.

Comparison to Industry Standards

• HEPLISAV-B's performance is strong compared to competitors like GlaxoSmithKline plc (Engerix-B, Twinrix) and Merck & Co (Recombivax-HB) in the hepatitis B vaccine market, especially given its two-dose regimen advantage over three-dose alternatives.
• The shingles vaccine candidate, Z-1018, demonstrated comparable immunogenicity to Shingrix (GSK's leading shingles vaccine) with a favorable tolerability profile, including lower solicited local and systemic post-injection reactions, positioning it as a potential best-in-class alternative.
• The collaboration with the U.S. Department of Defense for a plague vaccine candidate aligns with broader industry trends of public-private partnerships for biodefense and pandemic preparedness, similar to efforts seen during the COVID-19 pandemic.
• The Vaxart agreement for oral coronavirus vaccines represents a strategic move into a differentiated delivery platform, potentially offering a competitive advantage over traditional injectable vaccines for respiratory illnesses, similar to how oral polio vaccines revolutionized polio eradication.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for increased value through share repurchase programs and strategic pipeline expansion, but diluted EPS for 9M 2025 due to one-time charges. Stock price volatility remains a risk.
• **Employees**: Continued investment in R&D and commercialization efforts supports job stability and growth opportunities, but the loss of key personnel remains a risk.
• **Customers (HEPLISAV-B)**: Continued supply and market share growth of HEPLISAV-B ensures access to a two-dose hepatitis B vaccine.
• **Collaboration Partners (DoD, Vaxart)**: New and ongoing collaborations indicate strategic growth and potential for new product development, but the Clover situation highlights risks in partner payment collection.
• **Creditors (Convertible Note Holders)**: Refinancing of convertible notes extends maturity, reducing immediate repayment pressure, but the company's ability to service debt depends on future performance.

Next Steps

• Continue to drive long-term shareholder value by maximizing utilization of HEPLISAV-B.
• Expand the company's portfolio of innovative vaccine candidates leveraging CpG 1018 adjuvant technology.
• Leverage CpG 1018 adjuvant supply strategy through commercial and research collaborations.
• Pursue full collection of the $71.3 million due from Clover under the Clover Supply Agreement.
• Advance the shingles vaccine candidate (Z-1018) with topline Part 2 results and 12-month follow-up data for Part 1 expected in H2 2026.
• Continue clinical and manufacturing activities for the plague vaccine candidate in collaboration with the DoD through 2027.
• Evaluate the optimal formulation of CpG 1018 adjuvant in Part 2 of the Phase 1/2 trial for pandemic influenza, with topline data expected in 2026.
• Initiate clinical development for the Lyme disease vaccine candidate in 2027.
• Engage with the FDA to finalize the study protocol for the HEPLISAV-B hemodialysis observational retrospective cohort study.
• Execute the new $100.0 million share repurchase program authorized in October 2025.
• Proceed with the Vaxart Agreement, including the $25.0 million upfront license fee and $5.0 million equity investment, and potentially an additional $50.0 million fee after Phase 2b completion and End of Phase 2 meeting with the FDA.

Key Dates

Recommendation

Dynavax demonstrates strong underlying business performance with significant revenue growth for HEPLISAV-B and promising clinical pipeline advancements, particularly in shingles. The strategic Vaxart agreement and new share repurchase program are positive signals for future growth and shareholder value. However, the substantial net loss for the nine-month period, driven by a one-time debt extinguishment charge and a significant bad debt expense related to the Clover contract, introduces considerable financial volatility. While the core business is robust, these one-off events and ongoing risks related to CpG 1018 adjuvant demand and regulatory hurdles warrant a 'hold' recommendation. Investors should monitor the successful integration of the Vaxart platform, progress in the shingles and Lyme disease programs, and the resolution of the Clover receivable, as these will be key determinants of long-term value.

Keywords

HEPLISAV-B, Hepatitis B vaccine, CpG 1018 adjuvant, Vaccine development, Biopharmaceutical, Shingles vaccine, Plague vaccine, Lyme disease vaccine, Pandemic influenza vaccine, SEC filing, 10-Q, Financial results, Convertible notes, Share repurchase, Vaxart, Oral vaccines, SARS-CoV-2, COVID-19, Risk factors, Clinical trials, Regulatory approval, Biotech